GALAPAGOS SIGNS RESEARCH AGREEMENT

Galapagos announced today that it has entered into a research collaboration with Novartis Pharmaceuticals UK. Under the agreement, Galapagos' genomics partnering division Galadeno will design a research program for Novartis employing its SilenceSelect (gene knock-down) platform for functional assays in human primary cell assays. The SilenceSelect technology is based on Galadeno's collection of adenoviruses with human gene sequences that specifically knock down over 4,000 different human proteins by producing siRNA in a human cell. Under the terms of the agreement, Galadeno will provide technology, reagents and support to enable Novartis to validate drug targets by analyzing human protein function in human primary cells.

PrimeZone (http://www.primezone.com/newsroom/?d=81235)